Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 20

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 20
---
 that may be initiated by our shareholders, and therefore may           
 limit our shareholders’ ability to choose a forum for disputes with us or our directors, officers, employees, or agents                      |
| ● | Nevada law and provisions in our Articles of Incorporation and our new Nevada bylaws could make                                              
 a merger, tender offer or proxy contest difficult, thereby depressing the market price of our Common Stock.                                  |
| ● | We may be subject to securities litigation, which is expensive and could divert management attention.                                        |
| ● | FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our                                                      
 stock.                                                                                                                                       |
| ● | State securities laws may limit secondary trading, which may restrict the states in which you                                                
 can sell the shares purchased in this Offering.                                                                                              |

<div align='center'>8

RISK FACTORS</div>

Investing in our Common Stock involves a high degree of risk. Before investing in our Common Stock, you should carefully consider the risks described below, as well as the other information in this Prospectus, including our consolidated financial statements and the related notes. In addition, we may face additional risks and uncertainties not currently known to us, or which as of the date of this registration statement we might not consider significant, which may adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could be materially adversely affected. In such a case, the trading price of our Common Stock could decline due to any of these risks or uncertainties, and you may lose part or all of your investment.

Risks Related to our Business and Financial Condition

We have a history of losses and may never achieve profitability.

We are a development-stage biopharmaceutical company
and have incurred significant losses since inception. We expect to continue incurring operating losses for the foreseeable future and
we anticipate that we will incur operating losses and negative cash flow in the foreseeable future. We have not yet commercialized any
products and cannot be sure that we will ever be able to do so, or that we may ever achieve profitability. The amount of the accumulated
deficit will continue to increase, as it will be expensive to continue research, development and clinical efforts. If these activities
are successful and if we receive positive results from the clinical trials and subsequently from the FDA to market our novel therapies,
then even more funding will be required to market those. The outcome of these matters cannot be predicted at this time. We expect to expand
our clinical trials significantly